Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophageal Cancer Surgery Clear all
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

NCT01612546
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jul 22, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

NCT02714374
View directory record Official record
Conditions
Solid Organ Cancers
Interventions
GL-ONC1
Biological
Lead sponsor
Andrew Lowy
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 22, 2026, 2:29 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

NCT06721520
View directory record Official record
Conditions
Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions
Botulinum Toxin A (Botox ), Pyloromyotomy
Biological · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Results available

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

NCT01183559
View directory record Official record
Conditions
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Interventions
Vandetanib, 5 Fluorouracil (FU), Carboplatin, Paclitaxel, External Beam Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Esophageal Cancer Multimodal Prehabilitation Study

NCT06027515
View directory record Official record
Conditions
Esophageal Cancer, Esophageal Neoplasms
Interventions
Prehabilitation Program
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 2:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Prevention of Post-operative Pneumonia (POPP)

NCT01446874
View directory record Official record
Conditions
Post-operative Pneumonia, Lung Cancer, Esophageal Cancer
Interventions
0.12% chlorhexidine solution
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Jul 22, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

NCT00004897
View directory record Official record
Conditions
Esophageal Cancer
Interventions
recombinant interferon alfa, cisplatin, fluorouracil, hydroxyurea, leucovorin calcium, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery

NCT00011960
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, paclitaxel, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

NCT00086996
View directory record Official record
Conditions
Esophageal Cancer
Interventions
fluorouracil, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
143
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Jul 22, 2026, 2:29 PM EDT
Completed No phase listed Observational

Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation

NCT00839605
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Chest Wall Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 22, 2026, 2:29 PM EDT
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

NCT02965976
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2Phase 3 Interventional

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

NCT00002930
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 22, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

NCT01143545
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Jul 22, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

NCT03174275
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
Interventions
Durvalumab, Carboplatin, Nab-paclitaxel, Cisplatin, Surgical resection, IMRT
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

NCT00319735
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Radiation Therapy, Surgery, Tissue Sample
Procedure
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Galesburg, Illinois • Indianapolis, Indiana • Terre Haute, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00258323
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, Iressa, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jul 22, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00290719
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 2:29 PM EDT
Completed No phase listed Observational

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

NCT03095209
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer
Interventions
Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 22, 2026, 2:29 PM EDT
Withdrawn Phase 2 Interventional

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Jul 22, 2026, 2:29 PM EDT
Recruiting No phase listed Observational

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

NCT01416714
View directory record Official record
Conditions
Gastric Cancers
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00318903
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus
Interventions
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure), Esophagectomy (procedure)
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 22, 2026, 2:29 PM EDT
Completed Phase 2 Interventional

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Jul 22, 2026, 2:29 PM EDT